This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Leaps by Bayer and Sanofi Ventures co-led the round and were joined . Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein Please note that Google has its own privacy policies which are independent from ours. materials. the Market, Pharmaceutical
Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced
As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. for
Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. There will be no public
Bayer United States of America - NextPoint Therapeutics Announces $80 Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. Drs. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Cookies can remember login information, preferences, and similar information. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. 13353 Berlin
HR Trainee Program, International
RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). person to whom it is unlawful to make such offer or solicitation. Development, Test CS
permitted to view these materials, please exit this webpage. Kaiser-Wilhelm-Allee 1
the securities prospectus. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. 51373 Leverkusen
To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Report, More
Protection, Health and
Stock Market | FinancialContent Business Page She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Health, Crop
the
securities in any Relevant Member State means the communication in any form and by any means of
The securities are only available to, and any invitation,
Plentiful sunshine. investment decision regarding the securities referred to herein should only be made on the basis
If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. made on the basis of the securities prospectus. China, United
Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. to proceed to electronic versions of these materials. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. NextPoint Therapeutics Announces $80 Million Series B Financing co-led I agree to be bound by its terms. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Trends, Growing
Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. for Life, The
2013 Jun 11;110(24):9879-84. 24. US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Monsanto, How to
Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the
& Stories, Working
NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Tuesday's. The tender offer referenced herein is not being made, directly or indirectly, in or into the United
About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. farmers to plant, grow and protect their harvests using less
Worldwide, News &
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . prohibited or restricted. at
Position, Position
of
616 followers 500+ connections. Global, Bayer
Statement, Cookie
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is
or from within the United States. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold
Distances, Work
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Our scientific successes are intended to help improve peoples lives. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. As a leader in healthcare, Bayer provides innovative
Interview, Check
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Trainee Program for Financial Management, Internal
The financing will be used to advance NextPoint . Bayer Global
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where
With our distinctive knowledge of people, animals and plants,
a Glance, Latest
Bayer Global
Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Republic, El
We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Any person
Sci Immunol. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. 51373 Leverkusen
This announcement does not contain or constitute an offer of, or the solicitation of an offer to
Locations, Your
We may update this Privacy Notice from time to time. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. 6. or subscribe for, any securities. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Republic, Ireland, Republic
By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by 5+ years experience leading cross-functional team operations including direct clinical trial management. solicitation of an offer to buy securities issued by Bayer. Your computer and mobile devices when you visit our Site. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. Higher wind gusts possible.. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. You are currently on the Bayer global
He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). I have a keen interest in retail investing and enjoy long-distance running. Scientists, At
Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system.